Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance

Oncotarget

Volumn 7, Issue 26, 2016, Pages 39671-39679

  Yuan, Jiajia ^a   Zhang, Jie ^a   Zhu, Yan ^a   Li, Na ^b   Tian, Tiantian ^a   Li, Yang ^b   Li, Yanyan ^a   Li, Zhongwu ^a   Lai, Yumei ^a   Gao, Jing ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Advanced Cell Diagnostics   (China)

Author keywords

Advanced gastric cancer; Immunohistochemistry; Programmed death ligand 1; RNA in situ hybridization

Indexed keywords

MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MESENCHYME; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RNA IN SITU HYBRIDIZATION; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; MESODERM; METABOLISM; MIDDLE AGED; PROGNOSIS; STOMACH TUMOR; TISSUE DISTRIBUTION;

AGED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MESODERM; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA; RNA, MESSENGER; STOMACH NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84982883603     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9381     Document Type: Article

References (26)

1. Price TJ, Shaprio JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC. Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol. 2012; 6:199-208. doi: 10.1586/egh.11.103.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252-64. doi: 10.1038/nrc3239.
3. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192:1027-34. doi: 10.1084/jem.192.7.1027.
4. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013; 19:1021-34. doi: 10.1158/1078-0432.CCR-12-2063.
5. Chen L, Flies DB. Molecular mechanisms of T cell co-simulation and co-inhibition. Nat Rev Immunol. 2013; 13:227-42. doi:10.1038/nri3405.
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med. 2012; 366:2455-65. doi: 10.1056/NEJMoa1200694.
7. Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy. 2014; 6:459-75. doi: 10.2217/imt.14.9.
8. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010; 116:1757-66. doi: 10.1002/cncr.24899.
9. Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology. 2015; 27:39-46. doi: 10.1093/intimm/dxu095.
10. Merelli B, Massi D, Cattaneo L, Mandata M. Targeting the PD-1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2014; 89:140-65. doi: 10.1016/j.critrevonc.2013.08.002
11. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2010; 117:2192-201. doi: 10.1002/cncr.25747.
12. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinoma. Clin Cancer Res. 2014; 20:2773-82. doi: 10.1158/1078-0432.CCR-13-2702.
13. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014; 94:107-16. doi: 10.1038/labinvest.2013.130.
14. Muro K, Bang Y-J, Shankaran V, Geva R, Virgil D, Catenacci T, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, et al. Relationship between PD-L1 expression and clinical outcomes in patients(Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro: MK-3475) in KEYNOTE-012. J Clin Oncol. 2015(suppl 3, abstr 3).
15. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008; 52:797-805. doi: 10.1111/j.1365-2559.2008.03028.x.
16. Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014; 33:434-44. doi: 10.5732/cjc.014.10122.
17. Sznol M. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy. Cancer J. 2014; 20:290-5. doi: 10.1097/PPO.0000000000000056.
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443-54.
19. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, etal. Combined Nivolumab and Ipilimumab or monotherapy in Untreated melanoma. N Engl J Med. 2015; 373:23-34. doi: 10.1056/NEJMoa1504030.
20. Alba J, Gutierrez J, Coupe VM, Fernández B, VázquezBoquete Á, Alba J, Forteza J, García-Caballero T. HER2 status determination using RNA-ISH-a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer. Histol Histopathol. 2012; 27:1021-7.
21. Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, Luo H, Yang YX, Dai XY, Zhou SF, Wang D. Upregulation of PD-L1 and APEI is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015; 9:901-9. doi: 10.2147/DDDT.S75152.
22. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15:971-9. doi: 10.1158/1078-0432.CCR-08-1608.
23. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B, Wu X, Wang L, Wang J, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One. 2013; 8:e65821. doi: 10.1371/journal.pone.0065821.
24. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significant. Acta Histochem. 2006; 108:19-24. doi:10.1016/j.acthis.2006.01.003.
25. Yu J, Gao J, Lu Z, Gong J, Li Y, Dong B, Li Z, Zhang X, Shen L. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer. Eur J Cancer. 2014; 50:2328-35. doi: 10.1016/j.ejca.2014.06.017.
26. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-7. doi: 10.1038/nature14011.